Home › Research › Biomarkers
Blood-based biomarkers across the Alzheimer's disease continuum in older Korean population
Kang S, Choi YY, Kim M, Choi KY, Seo EH, Hwang H, Chung JY, Kim J et al.. medRxiv, 2026-10-29
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Plasma pTau217 best identified amyloid-PET positivity (AUC > 0.91). For AD diagnosis, adding cholesterol and glucose to pTau217 improved the AUC from 0.781 to 0.873. To predict progression in amyloid-positive individuals, glucose alone outperformed pTau217 (AUC 0.840 vs. 0.747), whereas adding GFAP yielded the strongest prognostic performance (AUC 0.867). Plasma pTau217 primarily reflects amyloid pathology, whereas metabolic markers provide complementary information related to the clinical expression and progression of the disease. Integrating biomarkers across distinct biological domains may improve risk stratification and prognostic assessment in AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kang, S., Choi, Y. Y., Kim, M., Choi, K. Y., Seo, E. H., Hwang, H., et al. (2026). Blood-based biomarkers across the Alzheimer's disease continuum in older Korean population. medRxiv. https://doi.org/10.64898/2026.10.27.26366659
Vancouver
Kang S, Choi YY, Kim M, Choi KY, Seo EH, Hwang H, et al. Blood-based biomarkers across the Alzheimer's disease continuum in older Korean population. medRxiv. 2026. doi:10.64898/2026.10.27.26366659.
BibTeX
@article{kang2026-650383db,
author = {Kang, S. and Choi, Y. Y. and Kim, M. and Choi, K. Y. and Seo, E. H. and Hwang, H. and Chung, J. Y. and Kim, J. and others},
title = {{Blood-based biomarkers across the Alzheimer's disease continuum in older Korean population}},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.10.27.26366659},
url = {https://doi.org/10.64898/2026.10.27.26366659}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Plasma pTau217 best identified amyloid-PET positivity (AUC > 0.91).
- For AD diagnosis, adding cholesterol and glucose to pTau217 improved the AUC from 0.781 to 0.873.
- To predict progression in amyloid-positive individuals, glucose alone outperformed pTau217 (AUC 0.840 vs. 0.747), whereas adding GFAP yielded the strongest prognostic performance (AUC 0.867).
- Plasma pTau217 primarily reflects amyloid pathology, whereas metabolic markers provide complementary information related to the clinical expression and progression of the disease.
- Integrating biomarkers across distinct biological domains may improve risk stratification and prognostic assessment in AD.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Effect sizeAUC 0.840; AUC 0.867
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 35 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 22 of the 62 points we could judge it on, which is 35 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 22 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 22 of the 62 points we could judge it on is 35 out of 100. |
| Total | 35 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.